We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$539M
AUM Growth
+$38.3M
Cap. Flow
+$82.7M
Cap. Flow %
15.36%
Top 10 Hldgs %
44.1%
Holding
265
New
51
Increased
68
Reduced
40
Closed
62

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$17M
2
SWTX
SpringWorks Therapeutics
SWTX
+$9.56M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.73M
4
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$8.5M
5
SEPN
Septerna Inc
SEPN
+$8.23M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$11.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$6.65M
4
EDR
Endeavor Group Holdings, Inc.
EDR
+$6.59M
5
SNY icon
Sanofi
SNY
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 78.09%
2 Financials 3.23%
3 Technology 0.19%
4 Consumer Discretionary 0.05%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFE icon
76
Pfizer
PFE
$153B
$1.04M 0.19%
41,050
+6,000
+17% +$157K
KDK
77
Kodiak AI
KDK
$865M
$1.01M 0.19%
90,466
-48,500
-35% -$536K
SGRY icon
78
Surgery Partners
SGRY
$2.03B
$950K 0.18%
+40,000
New +$947K
KNSA icon
79
Kiniksa Pharmaceuticals
KNSA
$5.93B
$920K 0.17%
41,412
-124,994
-75% -$2.57M
ACLX
80
DELISTED
Arcellx
ACLX
$916K 0.17%
13,962
+10,000
+252% +$677K
REGN icon
81
Regeneron Pharmaceuticals
REGN
$80.8B
$863K 0.16%
1,361
– –
KVACU
82
DELISTED
Keen Vision Acquisition Corp Units
KVACU
$842K 0.16%
75,000
– –
AGIO icon
83
Agios Pharmaceuticals
AGIO
$1.93B
$817K 0.15%
+27,900
New +$926K
GRCE
84
Grace Therapeutics
GRCE
$34.7M
$783K 0.15%
343,512
-430,123
-56% -$1.36M
KZR
85
DELISTED
Kezar Life Sciences
KZR
$719K 0.13%
147,404
– –
ARWR icon
86
Arrowhead Research
ARWR
$12.4B
$717K 0.13%
56,300
+43,400
+336% +$789K
SWTX
87
CALL
DELISTED
SpringWorks Therapeutics
SWTX
$662K 0.12%
+15,000
New +$690K
GPCR icon
88
Structure Therapeutics
GPCR
$3.78B
$617K 0.11%
35,619
+300
+0.8% +$7.35K
BIIB icon
89
Biogen
BIIB
$30.7B
$616K 0.11%
4,500
+1,455
+48% +$208K
ITOS
90
DELISTED
iTeos Therapeutics
ITOS
$604K 0.11%
101,096
-30,503
-23% -$224K
NTRA icon
91
Natera
NTRA
$46.4B
$601K 0.11%
+4,250
New +$683K
ZYME icon
92
Zymeworks
ZYME
$1.67B
$596K 0.11%
+50,000
New +$682K
LXEO icon
93
Lexeo Therapeutics
LXEO
$378M
$591K 0.11%
170,448
+943
+0.6% +$4.18K
KPRX icon
94
Kiora Pharmaceuticals
KPRX
$11.7M
$586K 0.11%
194,665
-5,556
-3% -$19.3K
SPRO icon
95
Spero Therapeutics
SPRO
$73M
$577K 0.11%
801,277
– –
BHVN icon
96
Biohaven
BHVN
$2.21B
$544K 0.1%
+22,641
New +$798K
TARA icon
97
Protara Therapeutics
TARA
$232M
$523K 0.1%
122,690
– –
USFR icon
98
WisdomTree Floating Rate Treasury Fund
USFR
$18.4B
$503K 0.09%
10,000
– –
ANSC
99
Agriculture & Natural Solutions Acquisition Corp
ANSC
$476M
$502K 0.09%
47,062
-33,300
-41% -$352K
LLY icon
100
Eli Lilly
LLY
$1.06T
$496K 0.09%
600
-750
-56% -$624K
2 3
4
5 6

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, ADAR1 Capital Management held 265 positions worth $539M, up 7.7% from $500M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

ADAR1 Capital Management deployed $82.7M of net new capital in Q1 2025, opening 51 new positions and adding to 68 existing holdings. Its largest new stake was SpringWorks Therapeutics: 207,778 shares worth $9.17M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $11.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2025 buy was SpringWorks Therapeutics: 207,778 shares worth $9.17M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q1 2025, an estimated $17M increase.
  • ADAR1 Capital Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $11.4M.
  • ADAR1 Capital Management fully exited Endeavor Group Holdings, Inc. in Q1 2025, selling an estimated $6.59M.
  • ADAR1 Capital Management's ten largest holdings make up 44% of its $539M portfolio in Q1 2025.
  • ADAR1 Capital Management opened 51 new positions and closed 62 in Q1 2025.
  • ADAR1 Capital Management's portfolio value rose 7.7% quarter-over-quarter to $539M.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.